Beau Semler, NP
Gerontology · Danville, INNPI 1972194561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by GSK at 26.6% of the total. Among gerontology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$895
- Regeneron Healthcare Solutions, Inc.$857
- Boehringer Ingelheim$650
- Mylan Specialty L.p.$350
- Amgen$294
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,74798%
- Education$1672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 121 | $1,838 |
| AstraZeneca | 36 | $895 |
| Regeneron Healthcare Solutions, Inc. | 30 | $857 |
| Boehringer Ingelheim | 30 | $650 |
| Mylan Specialty L.p. | 23 | $350 |
| Amgen | 8 | $294 |
| Sanofi | 15 | $280 |
| Inspire Medical Systems, Inc. | 2 | $271 |
| Pulmonx Corporation | 5 | $236 |
| Grifols USA, LLC | 10 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $156 |
| Intuitive Surgical | 1 | $130 |
| Baxter Healthcare | 4 | $123 |
| Electromed, Inc. | 12 | $109 |
| Philips North America LLC | 6 | $85 |
| Paratek Pharmaceuticals, Inc. | 1 | $85 |
| Verona Pharma, Inc. | 4 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Inogen, Inc. | 5 | $61 |
| Insmed, Inc. | 3 | $53 |
| Boston Scientific | 1 | $27 |
| Viatris Specialty LLC | 1 | $23 |
| Breas Medical, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$271
- DUPIXENT$239
- NUCALA$227
- CHARTIS CATHETER$155
- ZEPHYR DELIVERY CATHETER$155
- ZEPHYR ENDOBRONCHIAL VALVE$155
- PULMONX CHARTIS TABLET CONSOLE$155
- Da Vinci Surgical System$130
- TRELEGY ELLIPTA$117
- TEZSPIRE$116
- Tavneos$116
How this compares
$6,914 in reported general payments places this provider in the 95th percentile of 230 gerontology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 252 | $264,545 |
| OfevNintedanib Esylate | 19 | $242,881 |
| Dupixent PenDupilumab | 51 | $200,880 |
| Spiriva RespimatTiotropium Bromide | 104 | $96,672 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $89,227 |
| Dupixent SyringeDupilumab | 18 | $65,491 |
| Advair HfaFluticasone Propion/Salmeterol | 119 | $63,672 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $63,329 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $63,149 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $39,006 |
| Spiriva HandihalerTiotropium Bromide | 35 | $38,263 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $33,510 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 23 | $21,759 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $20,594 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $16,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $650 | $441,888230 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,838 | $384,749438 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $895 | $131,580163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 230 gerontology providers in Indiana.
Other gerontology in Danville
- Angela PattiMunster$44K
- Jessica KiszkaMunster$42K
- Sandra GarofaloIndianapolis$24K
- Megan MonnierBloomington$23K
- Diane BrackinFishers$13K
- Karie BeasleyEvansville$13K
- Mary ParkerFort Wayne$13K
- Morgan SlawsonMunster$9K
- Marena ArnoldFort Wayne$8K
- Emily HintonMunster$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.